Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.Journal of Clinical Oncology.  JCO2101935. 2021
2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myelomaBritish Journal of Haematology.  195:e113-e116. 2021
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
2021 Autologous stem cell transplantation in the age of ANDROMEDABritish Journal of Haematology.  193:865-866. 2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationBone Marrow Transplantation.  56:1364-1372. 2021
2021 Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapyLancet Haematology.  8:e386-e387. 2021
2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - ReplyJAMA Oncology.  7:635-636. 2021
2021 New regimens and directions in the management of newly diagnosed multiple myelomaAmerican Journal of Hematology.  96:367-378. 2021
2021 A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsBone Marrow Transplantation2021
2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLeukemia.  35:18-30. 2021
2021 Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myelomaJournal of Geriatric Oncology2021
2021 Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapiesLeukemia2021
2020 Age is just a number, the wrong numberCancer.  126:5014-5016. 2020
2020 Solid Organ Transplantation 2020
2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaBiology of Blood and Marrow Transplantation.  26:1394-1401. 2020
2020 Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the data 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations 2020
2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisJAMA Oncology.  6:1759-1765. 2020
2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline ChemoimmunotherapyBiology of Blood and Marrow Transplantation2020
2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myelomaBritish Journal of Haematology.  186:807-819. 2019
2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myelomaCancer Immunology Research.  7:1224-1229. 2019
2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancerJournal of Surgical Oncology.  114:323-328. 2016
2015 Myocardial perfusion imaging determination using an appropriate use smartphone applicationJournal of Nuclear Cardiology.  22:66-71. 2015
2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal Metastasis.Rivista di Neuroradiologia.  27:685-689. 2014
2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancerNuclear Medicine Communications.  32:52-58. 2011

Investigator On

  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by EUSA PHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012
  • Full Name

  • Susan Bal